Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities. | J Clin Med | 2023 | 37240564 | PubTator, text mining | PubMed |
| Evidence Synthesis of Gene Therapy and Gene Editing from Different Disorders-Implications for Individuals with Rett Syndrome: A Systematic Review. | Int J Mol Sci | 2023 | 37240368 | PubTator, text mining | PubMed |
| Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland. | Healthcare (Basel) | 2023 | 37239800 | PubTator, text mining | PubMed |
| Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples. | Biomedicines | 2023 | 37238925 | PubTator, text mining | PubMed |
| Clinical and Functional Characteristics of a New Phenotype of SMA Type I among a National Sample of Spanish Children: A Cross-Sectional Study. | Children (Basel) | 2023 | 37238440 | PubTator, text mining | PubMed |
| Pre-mRNA splicing and its cotranscriptional connections. | Trends Genet | 2023 | 37236814 | PubTator, text mining | PubMed |
| Detection of FLAD1 mutations and lipid storage myopathy in a 5-year-old boy: a case report study. | Ann Med Surg (Lond) | 2023 | 37229023 | PubTator, text mining | PubMed |
| HnRNPR strongly represses splicing of a critical exon associated with spinal muscular atrophy through binding to an exonic AU-rich element. | J Med Genet | 2023 | 37225410 | PubTator, text mining | PubMed |
| Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England. | Neurol Ther | 2023 | 37222861 | PubTator, text mining | PubMed |
| Pilot Program of Newborn Screening for 5q Spinal Muscular Atrophy in the Russian Federation. | Int J Neonatal Screen | 2023 | 37218894 | PubTator, text mining | PubMed |
| Cerebellar structural, astrocytic, and neuronal abnormalities in the SMNΔ7 mouse model of spinal muscular atrophy. | Brain Pathol | 2023 | 37218083 | PubTator, text mining | PubMed |
| [Results of carrier screening for Spinal muscular atrophy among 35 145 reproductive-aged individuals from Dongguan region]. | Zhonghua Yi Xue Yi Chuan Xue Za Zhi | 2023 | 37211998 | PubTator, text mining | PubMed |
| Stress granules: potential therapeutic targets for infectious and inflammatory diseases. | Front Immunol | 2023 | 37205103 | PubTator, text mining | PubMed |
| Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies. | EClinicalMedicine | 2023 | 37197706 | PubTator, text mining | PubMed |
| [Drug Administration for Childhood Neurological Disorders]. | Brain Nerve | 2023 | 37194546 | PubTator, text mining | PubMed |
| [Treatment of Spinal Muscular Atrophy]. | Brain Nerve | 2023 | 37194521 | PubTator, text mining | PubMed |
| Subjective Sleep Quality as it Relates to Cognitive and Physical Function in Spinal Muscular Atrophy Patients. | J Neuromuscul Dis | 2023 | 37182894 | PubTator, text mining | PubMed |
| RNA Transcript Diversity in Neuromuscular Research. | J Neuromuscul Dis | 2023 | 37182892 | PubTator, text mining | PubMed |
| Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis. | Front Pediatr | 2023 | 37181426 | PubTator, text mining | PubMed |
| How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? | BMC Health Serv Res | 2023 | 37179322 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=29